Mereo’s brittle bone drug likely to shrug off phase 2b fail, say analysts

Mereo’s drug candidate for brittle bone disease missed its primary endpoint in a recent phase 2b study, but analysts at Cantor Fitzgerald reckon that may not stop the drug getting approved.